Dental implant placement in patients with a history of medications related to osteonecrosis of the jaws: a systematic review

Sher, Judd, Kirkham-Ali, Kate, Luo, Jie Denny, Miller, Kate (Catherine M), and Sharma, Dileep (2021) Dental implant placement in patients with a history of medications related to osteonecrosis of the jaws: a systematic review. Journal of Oral Implantology, 47 (3). pp. 249-268.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website: https://doi.org/10.1563/aaid-joi-D-19-00...
 
1


Abstract

The present systematic review evaluates the safety of placing dental implants in patients with a history of antiresorptive or antiangiogenic drug therapy. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. PubMed, Cochrane Central Register of Controlled Trials, Scopus, Web of Science, and OpenGrey databases were used to search for clinical studies (English only) to July 16, 2019. Study quality was assessed regarding randomization, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other biases using a modified Newcastle-Ottawa scale and the Joanna Briggs Institute critical appraisal checklist for case series. A broad search strategy resulted in the identification of 7542 studies. There were 28 studies reporting on bisphosphonates (5 cohort, 6 case control, and 17 case series) and 1 study reporting on denosumab (case series) that met the inclusion criteria and were included in the qualitative synthesis. The quality assessment revealed an overall moderate quality of evidence among the studies. Results demonstrated that patients with a history of bisphosphonate treatment for osteoporosis are not at increased risk of implant failure in terms of osseointegration. However, all patients with a history of bisphosphonate treatment, whether taken orally for osteoporosis or intravenously for malignancy, appear to be at risk of “implant surgery-triggered” medication-related osteonecrosis of the jaw (MRONJ). In contrast, the risk of MRONJ in patients treated with denosumab for osteoporosis was found to be negligible. In conclusion, general and specialist dentists should exercise caution when planning dental implant therapy in patients with a history of bisphosphonate and denosumab drug therapy. Importantly, all patients with a history of bisphosphonates are at risk of MRONJ, necessitating this to be included in the informed consent obtained before implant placement.

Item ID: 69444
Item Type: Article (Research - C1)
ISSN: 1548-1336
Keywords: dental implants, antiresorptive drugs, antiangiogenic drugs, osseointegration, MRONJ
Related URLs:
Funders: James Cook University (JCU), Australian Dental Research Foundation (ADRF)
Projects and Grants: JCU College of Medicine and Dentistry Honours program, ADRF Colin Cormie Grant
Date Deposited: 27 Sep 2021 03:13
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3203 Dentistry > 320306 Oral implantology @ 80%
32 BIOMEDICAL AND CLINICAL SCIENCES > 3203 Dentistry > 320303 Dental therapeutics, pharmacology and toxicology @ 20%
SEO Codes: 20 HEALTH > 2001 Clinical health > 200105 Treatment of human diseases and conditions @ 80%
20 HEALTH > 2001 Clinical health > 200101 Diagnosis of human diseases and conditions @ 20%
Downloads: Total: 1
Last 12 Months: 1
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page